| Literature DB >> 28373243 |
Erik B Schelbert1, Uri Elkayam2, Leslie T Cooper3, Michael M Givertz4, Jeffrey D Alexis5, Joan Briller6, G Michael Felker7, Sandra Chaparro8, Angela Kealey9, Jessica Pisarcik10, James D Fett10, Dennis M McNamara10.
Abstract
BACKGROUND: In peripartum cardiomyopathy, the prevalence of focal myocardial damage detected by late gadolinium enhancement (LGE) cardiovascular magnetic resonance is important to elucidate mechanisms of myocardial injury and cardiac dysfunction. LGE equates irreversible myocardial injury, but LGE prevalence in peripartum cardiomyopathy is uncertain. METHODS ANDEntities:
Keywords: cardiovascular magnetic resonance; heart failure; myocardial fibrosis; peripartum cardiomyopathy; pregnancy and postpartum
Mesh:
Substances:
Year: 2017 PMID: 28373243 PMCID: PMC5533034 DOI: 10.1161/JAHA.117.005472
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Patient Characteristics According to Whether Cardiovascular Magnetic Resonance (CMR) Scans Were Performed
| Variable | CMR Performed (N=40) | No CMR Performed (N=60) |
|
|---|---|---|---|
| Demographics | |||
| Age, y, median (Q1–Q3) | 31 (27–33) | 30 (24–35) | 0.92 |
| Hispanic, n (%) | 8 (20%) | 7 (12%) | 0.27 |
| Black, n (%) | 9 (23%) | 21 (35%) | 0.27 |
| Days elapsed to enroll after delivery, median (Q1–Q3) | 22 (10–44) | 24 (12–52) | 0.40 |
| Comorbidity and past medical history | |||
| Diabetes mellitus, n (%) | 3 (8%) | 8 (13%) | 0.51 |
| Hypertension, n (%) | 18 (45%) | 27 (45%) | 1.00 |
| Smoking, n (%) | 13 (33%) | 22 (37%) | 0.44 |
| Substance abuse, n (%) | 3 (8%) | 7 (12%) | 0.74 |
| Autoimmune disease, n (%) | 2 (5%) | 3 (5%) | 1.00 |
| Family history of dilated cardiomyopathy, n (%) | 2 (5%) | 8 (13%) | 0.31 |
| Gravida, n (%) | 2 (1–4%) | 2 (1–4%) | 0.92 |
| Para, n (%) | 2 (1–3) | 2 (1–3) | 0.89 |
| Cesarean delivery, n (%) | 18 (45%) | 32 (53%) | 0.41 |
| Multiple birth, n (%) | 7 (18%) | 12 (20%) | 0.75 |
| NYHA class distribution (I, II, III, IV), n (%) | 7, 18, 9, 6 (18%, 45%, 23%, 15%) | 5, 28, 16, 11 (8%, 47%, 27%, 18%) | 0.57 |
| Biometrics | |||
| BMI, median (Q1–Q3) | 29 (24–35) | 27 (24–33) | 0.41 |
| Height, in, median (Q1–Q3) | 65 (64–66) | 63 (61–66) | 0.05 |
| Weight, lbs, median (Q1–Q3) | 177 (132–216) | 149 (130–191) | 0.29 |
| Systolic blood pressure, mm Hg, median (Q1–Q3) | 109 (98–118) | 110 (100–128) | 0.38 |
| Diastolic blood pressure, mm Hg, median (Q1–Q3) | 71 (59–80) | 68 (62–79) | 0.77 |
| Heart rate, bpm, median (Q1–Q3) | 86 (75–100) | 86 (72–99) | 0.40 |
| Medications | |||
| Inotropes, n (%) | 4 (10%) | 11 (18%) | 0.25 |
| ACE inhibitors, n (%) | 32 (80%) | 40 (80%) | 1.00 |
| Angiotensin receptor blocker, n (%) | 1 (3%) | 0 (0%) | 0.40 |
| β‐Blocker, n (%) | 34 (85%) | 54 (90%) | 0.54 |
| Diuretic, n (%) | 27 (68%) | 43 (72%) | 0.66 |
| Digoxin, n (%) | 3 (8%) | 5 (8%) | 1.00 |
| Laboratories | |||
| Sodium, median (Q1–Q3) | 139 (137–141) | 139 (137–141) | 0.34 |
| BUN, median (Q1–Q3) | 13 (9–16) | 14 (10–20) | 0.23 |
| Cr, median (Q1–Q3) | 0.85 (0.70–1.00) | 0.80 (0.70–1.00) | 0.74 |
| Hematocrit, %, median (Q1–Q3) | 35 (31–38) | 35 (32–39) | 0.78 |
| White blood cells, median (Q1–Q3) | 7.8 (5.6–9.8) | 7.2 (6.0–9.0) | 0.65 |
ACE indicates angiotensin‐converting enzyme; BMI, body mass index; bpm, beats per minute; BUN, blood urea nitrogen; Cr, creatinine; NYHA, New York Heart Association.
Cardiovascular Magnetic Resonance (CMR) Data for Those With Paired Studies (n=22)
| CMR Parameter | Baseline CMR Scan | 6‐Month CMR Scan | Difference |
|
|---|---|---|---|---|
| LV ejection fraction (%), median (Q1–Q3) | 41 (31–53) | 57 (51–60) | 11 (3–24) | <0.001 |
| LV end diastolic volume, mL, median (Q1–Q3) | 171 (137–259) | 145 (124–167) | −22 (−55 to 0) | <0.001 |
| LV end diastolic volume index, mL/m2, median (Q1–Q3) | 101 (81–129) | 84 (70–96) | −12 (−32 to 0) | <0.001 |
| LV end systolic volume, mL, median (Q1–Q3) | 101 (63–171) | 60 (52–74) | −25 (−74 to −7) | <0.001 |
| LV end systolic volume index, mL/m2, median (Q1–Q3) | 64 (36–92) | 34 (30–42) | −13 (−38 to −5) | <0.001 |
| LV mass, g (Q1–Q3) | 94 (80–112) | 79 (58–104) | −22 (−32 to −2) | 0.009 |
| LV mass index, g/m2 (Q1–Q3) | 56 (44–62) | 43 (34–55) | −12 (−18 to −1) | 0.009 |
| Prevalence of LGE, N (%) | 2 (9%) | 3 (14%) | 1 (5%) | 0.31 |
LGE indicates late gadolinium enhancement; LV, left ventricular.
For the 20 individuals with paired data; P value reflects McNemar's test.
Figure 1Left ventricular ejection fraction improved over time in most participants (A), resulting from decreased end diastolic volumes (B) and end systolic volumes (C) at 6 months compared to baseline. Since cardiovascular magnetic resonance (CMR) occurred 31±24 days postpartum, some women exhibited significant recovery by the time they were scanned. The 2 women with the worst ejection fraction at 6 months exhibited evidence of pathology distinct from the others (A, adjacent thumbnail insets). One woman exhibited marked trabeculations on cine images suggesting left ventricular noncompaction cardiomyopathy (arrow), and the other woman exhibited focal myocardial scar on late gadolinium enhancement (LGE) images indicating irreversible myocardial injury (arrow) also shown in Figure 2C. Alternate pathologies may exist given the nonspecific diagnostic criteria of peripartum cardiomyopathy.
Figure 2Examples of focal myocardial damage detected by late gadolinium enhancement (LGE, arrows) in 3 participants. In (C), the 2‐chamber orientation is rotated, rendering the LGE not clearly visible. None of these participants exhibited extensive myocardial damage, and none experienced adverse events. The LGE pattern in patient in (A) resembles the injury pattern in myocarditis. The 6‐month left ventricular ejection fractions were 53%, 41%, and 19% for the participants in (A through C), respectively. Coronary artery disease in the patients in (B and C) could not be excluded definitively. Given: (1) the low pretest probability of coronary disease in younger premenopausal women, and (2) the limited involvement in the long‐axis direction (ie, base to apex) that is unusual for coronary disease, we believed the probability of coronary artery disease was low. Still, we could not exclude vasospasm, embolization, cocaine, or recanalized myocardial infarction as potential etiologies.
Figure 3No late gadolinium enhancement (LGE) was detected for the 2 individuals who died (A and B). The woman in (A) had a measured left ventricular ejection fraction of 15%, and died after left ventricular assist device implantation and eventual orthotopic heart transplantation. The woman in (B) had a measured left ventricular ejection fraction of 17% and died prior to surgical interventions.